Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is a promising clinical-stage biotechnology company with a portfolio of targeted therapies for multiple solid tumors, which is differentiated from other therapies through its comprehensive and unique mechanism of action. With positive Phase 3 PFS results in both PIK3CA WT and MT subgroups and a planned sNDA filing after the upcoming July PDUFA decision, the company is positioned for potential pan-PIK3CA coverage. Celcuity's decision to expand its 1L program with a simplified Phase 3 design and initiation of development for a subcutaneous formulation further solidify the company's growth potential. Despite the risks associated with clinical, technology, regulatory, manufacturing, commercial, legal and intellectual property, competition, and dilution, the company's impressive financials, including a projected 12-month price target of $185 per diluted share, make it a favorable investment opportunity.

Bears say

Celcuity is a clinical-stage biotechnology company that is focused on developing targeted therapies for multiple types of cancer. While the company's lead candidate, gedatolisib, shows promise in clinical studies, the competitive nature of the drug development industry and the need for additional funding present potential risks for the company's success. The company's financial outlook may also be impacted by its ability to receive milestone payments or attract partners.

Celcuity (CELC) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.